Market Place
Sourcing Support
Taiho Pharma`s Lytgobi (futibatinib) Receives Approval in Europe
19 Oct 2023 //
EMA
Boundless Bio Announces Agreement with Taiho Oncology to Evaluate LYTGOBI
18 Sep 2023 //
BUSINESSWIRE
Taiho`s Lytgobi (futibatinib) Receives Approval in Europe
18 Jul 2023 //
EMA
EC Grants Conditional Marketing Authorization for Taiho`s Lytgobi Tablets
05 Jul 2023 //
PR NEWSWIRE
Chmp Issues Positive Opinion For Futibatinib For The Treatment
27 Apr 2023 //
PR NEWSWIRE
Lytgobi Now Available from Onco360 for the Treatment of Adult Patients
13 Feb 2023 //
BUSINESSWIRE
Taiho to Publish in The New England Journal of Medicine for Futibatinib
18 Jan 2023 //
PR NEWSWIRE
2022 drug approvals: Biopharma delivered 37 new drugs
03 Jan 2023 //
FIERCE PHARMA
FDA greenlights Otsuka subsidiary`s bile duct cancer drug
04 Oct 2022 //
ENDPTS
Taiho Oncology To Present Data on Futibatinib (TAS-120) at the AACR
04 Jun 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.